Cosciens Biopharma Total Payout Ratio Related Terms
Cosciens Biopharma Total Payout Ratio Historical Data
* Premium members only.
The historical data trend for Cosciens Biopharma's Total Payout Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CSCID vs VRTX, REGN, ALNY: Total Payout Ratio Comparison
For the Biotechnology subindustry, Cosciens Biopharma's Total Payout Ratio, along with its competitors' market caps and Total Payout Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Cosciens Biopharma Total Payout Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Cosciens Biopharma's Total Payout Ratio distribution charts can be found below:
* The bar in red indicates where Cosciens Biopharma's Total Payout Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cosciens Biopharma (CSCID) has a Total Payout Ratio of 0.00 as of Jul. 08, 2026. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Total Payout Ratio too high?
Cosciens Biopharma's current Total Payout Ratio is 0.00. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Total Payout Ratio compare to VRTX and REGN?
Cosciens Biopharma's Total Payout Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Payout Ratio for a Biotechnology company?
A good Total Payout Ratio depends on the Biotechnology industry context. However, Total Payout Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Payout Ratio mean?
A high Total Payout Ratio can signal that a stock is expensive relative to its fundamentals. Total Payout Ratio is the percent a company has paid to its shareholders through net repurchase of shares and dividends based on its Net Income. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Total Payout Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCID) is currently considered Fairly Valued. The stock's GF Value™ is $6.57, compared to a current price of $7.00 — trading 6.5% above its estimated fair value. The current Total Payout Ratio is 0.00. Cosciens Biopharma's overall GF Score™ is 61/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Payout Ratio calculated?
Total Payout Ratio is calculated from a company's financial statements. For Cosciens Biopharma (CSCID), the current Total Payout Ratio is 0.00 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Cosciens Biopharma (CSCID) Overvalued in 2026?
Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be overvalued.
The current stock price of $7.00 is trading 6.5% above its estimated GF Value™ of $6.57.
GuruFocus considers Cosciens Biopharma to be Fairly Valued.
Key valuation signals for CSCID:
Total Payout Ratio: 0.00
GF Value™: $6.57 vs. price of $7.00 (6.5% above fair value)
No single metric tells the full story. See the CSCID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score
Get the complete analysis for CSCID
Total Payout Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSCID has been successfully added to your 
